BLOG

Redhill Planning NDA For H. Pylori Antibiotic Following Second Phase III Readout

RedHill Biopharma Ltd. plans to submit an NDA to FDA next half for Talicia (RHB-105) as first-line treatment of Helicobacter pylori infection regardless of ulcer status after reporting that the antibiotic met the primary endpoint in the Phase III ERADICATE Hp2 trial in the indication.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}